Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $211.65 | Total: $1,058.25 |
| 1 | 10 | $179.28 | Total: $1,792.80 |
| 1 | 25 | $151.89 | Total: $3,797.25 |
| 1 | 50 | $129.48 | Total: $6,474.00 |
| 1 | 100 | $112.05 | Total: $11,205.00 |
Overview
MBC-11 is a first-in-class conjugate of the bone-targeting bisphosphonate etidronate covalently linked to the antimetabolite cytarabine (araC), with potential to treat tumor-induced bone disease (TIBD).
Chemical Properties
| Molecular Formula | C11H20N3O14P3 |
| Molecular Weight | 511.21 |
| CAS Numbers | 332863-86-2 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | O[C@@H]1[C@@H](O[C@H](COP(OP(C(P(=O)(O)O)(C)O)(=O)O)(=O)O)[C@H]1O)N2C(=O)N=C(N)C=C2 |
Storage and Handling
0C Short Term, -20C Long Term
References
Reinholz MM, et al. A promising approach for treatment of tumor-induced bone diseases utilizing bisphosphonate derivatives of nucleoside antimetabolites. Bone. 2010 Jul;47[1] 12-22.